GSK wins Hibsago approval as analysts set target for GSK stock at GBp 2,064.38

Published on 10/26/2026 at 09:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hibsago won US approval on October 21, 2026, adding a hepatitis B option. GSK stock costs EUR 22.72 on October 26, 2026, 0.49 percent above Xetra.

Pipeline approval and earnings calendar

Hibsago received US approval on October 21, 2026, after Phase 3 trials produced a 19 percent functional cure rate.
GSK reaffirmed 2026 core operating profit growth of 7 percent to 9 percent in its October 8, 2026 outlook.
GSK stock trades at EUR 22.72 at 9:49 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.49 percent above the Xetra close of October 23, 2026.
GSK is scheduled to report third-quarter results on October 28, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) is trading at EUR 22.72 at Lang & Schwarz on October 26, 2026, at 9:49 a.m. CEST, 0.49 percent above the Xetra close of October 23, 2026 at EUR 22.61. The latest company catalyst is Hibsago, which won US approval for certain adults with chronic hepatitis B on October 21, 2026, according to Morningstar.

Hibsago adds a commercial asset

The approval covers patients without cirrhosis who have received nucleoside analogue therapy for at least six months. The treatment is given over six months, with an option for administration at home after the first dose, according to the release carried by Morningstar.

Phase 3 B-Well data showed a 19 percent functional cure rate among 1,220 treated participants, compared with 0 of 614 in the placebo group. The result gives GSK a new approved asset, but the treatment also carries warnings on hepatic flares, thrombocytopenia and renal function.

What does the outlook mean?

GSK's October 8, 2026 aide memoire reaffirmed full-year 2026 guidance for turnover growth of 3 percent to 5 percent at constant exchange rates. It also pointed to core operating profit and core earnings per share growth of 7 percent to 9 percent, with operating profit expected in the upper half of the range, according to GSK.

For context, GSK reported second-quarter revenue of USD 11.14 billion and earnings per share of USD 1.36 on July 28, 2026, against a consensus estimate of USD 1.27, according to MarketBeat. The next report will show whether Hibsago and the wider specialty-medicines portfolio can offset pressure from legal charges and research setbacks.

Three dates frame the stock

On July 28, 2026, GSK reported USD 11.14 billion in quarterly revenue and USD 1.36 earnings per share. On October 6, 2026, GSK admitted 19,352 ordinary shares to London trading, according to Financial Times. On October 21, 2026, Hibsago received US approval after Phase 3 data showed a 19 percent functional cure rate.

Upcoming dates for GSK

GSK is scheduled to publish third-quarter results on October 28, 2026. The company also highlighted an oncology update for October 27, 2026, ahead of the results.

Stock trades above Xetra close

The London-listed company has a market capitalization of USD 101.7 billion as of October 23, 2026, while its 52-week range was USD 42.89 to USD 61.70. The quoted euro price remains the clearest short-term reference for investors in Germany.

GSK was trading at EUR 22.72 at Lang & Schwarz on October 26, 2026, at 9:49 a.m. CEST, 0.49 percent above the Xetra close of October 23, 2026 at EUR 22.61. The further course of trading is shown by the continuously updated real-time quote of GSK stock.